Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank.
Am Heart J
; 270: 23-43, 2024 04.
Article
en En
| MEDLINE
| ID: mdl-38242417
ABSTRACT
The global pharmaceutical industry portfolio is skewed towards cancer and rare diseases due to more predictable development pathways and financial incentives. In contrast, drug development for major chronic health conditions that are responsible for a large part of mortality and disability worldwide is stalled. To examine the processes of novel drug development for common chronic health conditions, a multistakeholder Think Tank meeting, including thought leaders from academia, clinical practice, non-profit healthcare organizations, the pharmaceutical industry, the Food and Drug Administration (FDA), payors as well as investors, was convened in July 2022. Herein, we summarize the proceedings of this meeting, including an overview of the current state of drug development for chronic health conditions and key barriers that were identified. Six major action items were formulated to accelerate drug development for chronic diseases, with a focus on improving the efficiency of clinical trials and rapid implementation of evidence into clinical practice.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Salud Pública
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Am Heart J
Año:
2024
Tipo del documento:
Article